NovaBridge Biosciences
NBP
Get informed when a big investor buys or sells
+ FollowMarket Cap$149.28M
Close$
$0.11
91.7% downside
Current Fair Value
91.7% downsideOvervalued by 91.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $149.28 Million |
|---|---|
| Enterprise Value | $-12,644,200.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.16 |
| Beta | 1.6 |
| Outstanding Shares | 115,720,000 |
Return
| Return on Equity | -19.42% |
|---|---|
| Return on Assets | -18.48% |
| Return on Invested Capital | -18.50% |
Valuation & Multiples
| P/E Ratio | -2.44 |
|---|---|
| PEG | 2 |
| Price to Sales | - |
| Price to Book Ratio | 1.29 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.3 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$33.57 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About I-Mab
30 employees
CEO: Srishti Gupta NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a b...